Literature DB >> 26997924

RARtool: A MATLAB Software Package for Designing Response-Adaptive Randomized Clinical Trials with Time-to-Event Outcomes.

Yevgen Ryeznik1, Oleksandr Sverdlov2, Weng Kee Wong3.   

Abstract

Response-adaptive randomization designs are becoming increasingly popular in clinical trial practice. In this paper, we present RARtool, a user interface software developed in MATLAB for designing response-adaptive randomized comparative clinical trials with censored time-to-event outcomes. The RARtool software can compute different types of optimal treatment allocation designs, and it can simulate response-adaptive randomization procedures targeting selected optimal allocations. Through simulations, an investigator can assess design characteristics under a variety of experimental scenarios and select the best procedure for practical implementation. We illustrate the utility of our RARtool software by redesigning a survival trial from the literature.

Entities:  

Keywords:  MATLAB; adaptive design; censored data; delayed responses; multi-objective clinical trial; optimal allocation; response-adaptive randomization; survival trial

Year:  2015        PMID: 26997924      PMCID: PMC4792101          DOI: 10.18637/jss.v066.i01

Source DB:  PubMed          Journal:  J Stat Softw        ISSN: 1548-7660            Impact factor:   6.440


  8 in total

1.  On the use and utility of the Weibull model in the analysis of survival data.

Authors:  Kevin J Carroll
Journal:  Control Clin Trials       Date:  2003-12

Review 2.  Adaptive randomization for clinical trials.

Authors:  William F Rosenberger; Oleksandr Sverdlov; Feifang Hu
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

3.  Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.

Authors:  S E Jones; J Erban; B Overmoyer; G T Budd; L Hutchins; E Lower; L Laufman; S Sundaram; W J Urba; K I Pritchard; R Mennel; D Richards; S Olsen; M L Meyers; P M Ravdin
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

4.  Maximizing power and minimizing treatment failures in clinical trials.

Authors:  William F Rosenberger; Feifang Huc
Journal:  Clin Trials       Date:  2004       Impact factor: 2.486

5.  Optimal response-adaptive randomized designs for multi-armed survival trials.

Authors:  Oleksandr Sverdlov; Yevgen Tymofyeyev; Weng Kee Wong
Journal:  Stat Med       Date:  2011-08-08       Impact factor: 2.373

6.  Efficient and ethical response-adaptive randomization designs for multi-arm clinical trials with Weibull time-to-event outcomes.

Authors:  Oleksandr Sverdlov; Yevgen Ryeznik; Weng-Kee Wong
Journal:  J Biopharm Stat       Date:  2014       Impact factor: 1.051

7.  Continuous Bayesian adaptive randomization based on event times with covariates.

Authors:  Ying Kuen Cheung; Lurdes Y T Inoue; J Kyle Wathen; Peter F Thall
Journal:  Stat Med       Date:  2006-01-15       Impact factor: 2.373

8.  An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.

Authors:  David J Adelstein; Yi Li; George L Adams; Henry Wagner; Julie A Kish; John F Ensley; David E Schuller; Arlene A Forastiere
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

  8 in total
  1 in total

1.  Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes.

Authors:  Yevgen Ryeznik; Oleksandr Sverdlov; Andrew C Hooker
Journal:  AAPS J       Date:  2017-12-28       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.